3Daughters Secures $4.7 million in Oversubscribed Seed Round
Funds will support development of game-changing IUD (intrauterine device) for contraception through an IND filing in early 2025 (more…)
3Daughters to Participate in Women’s Health Panel During the 2024 BIO International Convention in San Diego, CA, June 3-6
Mansfield, MA., May 23, 2024 – 3Daughters, Inc., a clinical development company fueling evolutionary healthcare for women, announced that Mary Beth Cicero, Co-Founder and CEO, will participate in an expert…
3Daughters Named “Startup of the Year” at BioLabs Philadelphia Investor Day 2024
Mansfield, MA., April 19, 2024 – 3Daughters, Inc., a clinical development company fueling evolutionary healthcare for women, was voted the “Startup of Year” by top life science investors and venture…
3Daughters Announces Three New Appointments to Board of Directors
Board will help advance the mission and support development of our game-changing IUD for contraception (3D-001) Mansfield, MA., March 12, 2024 – 3Daughters, a clinical development company fueling evolutionary healthcare…
3DaughtersTM Successfully Closes Over $2 million in First Tranche of Seed Financing Round
Funding will accelerate development of a Novel IUD for contraception for IND filing in 2024 MANSFIELD, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- 3Daughters, a clinical development company fueling evolutionary…
3DaughtersTM Emerges as a Transformative Women’s Healthcare Company and Announces Key Leadership and Scientific Advisory Board Appointments
3Daughters aims to uniquely address and fill major gaps in Women’s Health Assembles experienced Women’s Health team and World Class SAB to advance development of novel long-acting reversible contraception technology…
